Zareen Ahmed, MD
Internal Medicine · Salisbury, MDNPI 1407039043
Payments from drug & device makers
Across 67 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$223
- AbbVie$111
- GSK$110
- Novo Nordisk$104
- Pfizer$93
- Astellas Pharma US Inc$82
- plus $583 from 17 others
What the payments were for
- Food & beverage$1,307100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $223 |
| AbbVie | 6 | $111 |
| GSK | 5 | $110 |
| Novo Nordisk | 6 | $104 |
| Pfizer | 5 | $93 |
| Astellas Pharma US Inc | 4 | $82 |
| Harmony Biosciences LLC | 3 | $67 |
| Sanofi-aventis U.S. LLC | 2 | $64 |
| Amgen | 3 | $62 |
| Boehringer Ingelheim | 3 | $53 |
| AstraZeneca | 3 | $47 |
| Biogen | 2 | $43 |
| Exact Sciences | 2 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Medtronic | 1 | $24 |
| BD | 1 | $24 |
| Abbott | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Indivior Inc. | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $14 |
How this compares
$1,307 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 82 | $1,490 |
| Rosuvastatin Calcium | 29 | $807 |
| Amlodipine Besylate | 70 | $681 |
| Carvedilol | 15 | $595 |
| Lisinopril | 47 | $501 |
| Pravastatin Sodium | 26 | $431 |
| Metoprolol Succinate | 24 | $360 |
| Levothyroxine Sodium | 51 | $327 |
| Montelukast Sodium | 15 | $327 |
| Metoprolol Tartrate | 15 | $322 |
| Tamsulosin Hcl | 22 | $307 |
| Losartan Potassium | 21 | $302 |
| Omeprazole | 17 | $256 |
| Fluticasone Propionate | 34 | $253 |
| Pantoprazole Sodium | 15 | $250 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Salisbury
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.